Abstract
Out of 46 patients treated by an intermittent HGH regime, 5 pts. with isol. HGH deficiency (IGHD) and 5 pts. with panhypopituitarism (CGHD) are presented. HGH was administered thrice weekly, 1–3 mg/injection, in courses of 3–14 months duration interspaced by intervals of 2–15 months. The patients received from 3–6 courses over a period of 2 3/12–6 3/12 years. This therapeutic schedule was found to be effective and in contradistinction to the continuous therapeutic schedule there was no progressive decline in growth-velocity. The patients with IGHD were found to respond better than those with CGHD, both in the first course as well as in consecutive courses. When compared to a long-term continuous therapeutic schedule (Table), our regime led to same growth achievement, saving the hormone which is scarce in its availability.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pertzelan, A., Kauli, R., Assa, S. et al. THE ADVANTAGE OF INTERMITTENT HGH THERAPY IN PATIENTS WITH ISOLATED AND COMBINED HGH DEFICIENCY. Pediatr Res 9, 689 (1975). https://doi.org/10.1203/00006450-197508000-00136
Issue Date:
DOI: https://doi.org/10.1203/00006450-197508000-00136